AIM ImmunoTech Inc. (AIM)
USD 0.09
(-19.37%)
USD 0.09
(-19.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 19.38 Million USD | -52.13% |
| 2022 | 40.48 Million USD | -29.83% |
| 2021 | 57.69 Million USD | -10.66% |
| 2020 | 64.58 Million USD | 219.42% |
| 2019 | 20.21 Million USD | 46.04% |
| 2018 | 13.84 Million USD | -2.55% |
| 2017 | 14.2 Million USD | -24.72% |
| 2016 | 18.87 Million USD | -17.24% |
| 2015 | 22.8 Million USD | -22.54% |
| 2014 | 29.44 Million USD | -7.62% |
| 2013 | 31.86 Million USD | -44.77% |
| 2012 | 57.69 Million USD | 32.6% |
| 2011 | 43.51 Million USD | -15.8% |
| 2010 | 51.68 Million USD | -20.48% |
| 2009 | 64.99 Million USD | 391.97% |
| 2008 | 13.21 Million USD | -42.91% |
| 2007 | 23.14 Million USD | -26.37% |
| 2006 | 31.43 Million USD | 27.4% |
| 2005 | 24.67 Million USD | -1.99% |
| 2004 | 25.17 Million USD | 87.79% |
| 2003 | 13.4 Million USD | 121.92% |
| 2002 | 6.04 Million USD | -49.81% |
| 2001 | 12.03 Million USD | -7.9% |
| 2000 | 13.06 Million USD | -7.98% |
| 1999 | 14.2 Million USD | -12.88% |
| 1998 | 16.3 Million USD | 41.74% |
| 1997 | 11.5 Million USD | 64.29% |
| 1996 | 7 Million USD | -44.88% |
| 1995 | 12.7 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 16.18 Million USD | -16.63% |
| 2024 Q2 | 15.71 Million USD | -2.93% |
| 2023 Q3 | 27.86 Million USD | -17.12% |
| 2023 FY | 19.41 Million USD | -52.04% |
| 2023 Q4 | 19.41 Million USD | -30.3% |
| 2023 Q2 | 33.61 Million USD | -10.26% |
| 2023 Q1 | 37.46 Million USD | -7.47% |
| 2022 Q1 | 54.15 Million USD | -6.14% |
| 2022 FY | 40.48 Million USD | -29.83% |
| 2022 Q4 | 40.48 Million USD | -12.52% |
| 2022 Q3 | 46.28 Million USD | -9.04% |
| 2022 Q2 | 50.88 Million USD | -6.04% |
| 2021 Q3 | 63.08 Million USD | -5.46% |
| 2021 FY | 57.69 Million USD | -10.66% |
| 2021 Q4 | 57.69 Million USD | -8.53% |
| 2021 Q1 | 74.08 Million USD | 14.72% |
| 2021 Q2 | 66.72 Million USD | -9.94% |
| 2020 Q3 | 64.16 Million USD | 28.01% |
| 2020 Q4 | 64.58 Million USD | 0.65% |
| 2020 FY | 64.58 Million USD | 219.42% |
| 2020 Q1 | 42.4 Million USD | 109.74% |
| 2020 Q2 | 50.12 Million USD | 18.2% |
| 2019 Q4 | 20.21 Million USD | -10.1% |
| 2019 FY | 20.21 Million USD | 46.04% |
| 2019 Q2 | 13.8 Million USD | -13.51% |
| 2019 Q3 | 22.49 Million USD | 62.88% |
| 2019 Q1 | 15.96 Million USD | 15.31% |
| 2018 Q3 | 15.17 Million USD | -3.28% |
| 2018 FY | 13.84 Million USD | -2.55% |
| 2018 Q4 | 13.84 Million USD | -8.73% |
| 2018 Q2 | 15.68 Million USD | -3.54% |
| 2018 Q1 | 16.26 Million USD | 14.45% |
| 2017 Q1 | 16.86 Million USD | -10.65% |
| 2017 FY | 14.2 Million USD | -24.72% |
| 2017 Q4 | 14.2 Million USD | -3.52% |
| 2017 Q3 | 14.72 Million USD | -8.59% |
| 2017 Q2 | 16.1 Million USD | -4.48% |
| 2016 Q2 | 21.91 Million USD | 1.94% |
| 2016 Q4 | 18.87 Million USD | -12.53% |
| 2016 Q1 | 21.5 Million USD | -5.72% |
| 2016 Q3 | 21.57 Million USD | -1.56% |
| 2016 FY | 18.87 Million USD | -17.24% |
| 2015 Q1 | 30.79 Million USD | 4.59% |
| 2015 Q2 | 29.86 Million USD | -3.0% |
| 2015 Q3 | 26.49 Million USD | -11.28% |
| 2015 FY | 22.8 Million USD | -22.54% |
| 2015 Q4 | 22.8 Million USD | -13.94% |
| 2014 FY | 29.44 Million USD | -7.62% |
| 2014 Q1 | 35.01 Million USD | 9.86% |
| 2014 Q3 | 30.63 Million USD | -8.68% |
| 2014 Q4 | 29.44 Million USD | -3.91% |
| 2014 Q2 | 33.54 Million USD | -4.17% |
| 2013 Q3 | 42.87 Million USD | -7.08% |
| 2013 Q4 | 31.86 Million USD | -25.68% |
| 2013 Q1 | 51.65 Million USD | -10.47% |
| 2013 Q2 | 46.14 Million USD | -10.68% |
| 2013 FY | 31.86 Million USD | -44.77% |
| 2012 Q2 | 41.11 Million USD | -3.8% |
| 2012 Q3 | 48.57 Million USD | 18.17% |
| 2012 FY | 57.69 Million USD | 32.6% |
| 2012 Q4 | 57.69 Million USD | 18.78% |
| 2012 Q1 | 42.73 Million USD | -1.79% |
| 2011 Q1 | 51.68 Million USD | 0.0% |
| 2011 FY | 43.51 Million USD | -15.8% |
| 2011 Q3 | 45.53 Million USD | -4.35% |
| 2011 Q2 | 47.6 Million USD | -7.89% |
| 2011 Q4 | 43.51 Million USD | -4.44% |
| 2010 Q1 | 60.88 Million USD | -6.32% |
| 2010 Q2 | 57.58 Million USD | -5.42% |
| 2010 Q4 | 51.68 Million USD | -7.51% |
| 2010 FY | 51.68 Million USD | -20.48% |
| 2010 Q3 | 55.87 Million USD | -2.97% |
| 2009 FY | 64.99 Million USD | 391.97% |
| 2009 Q1 | 12.39 Million USD | -6.2% |
| 2009 Q2 | 48.44 Million USD | 290.92% |
| 2009 Q3 | 67.69 Million USD | 39.74% |
| 2009 Q4 | 64.99 Million USD | -3.99% |
| 2008 Q2 | 17.49 Million USD | -14.08% |
| 2008 FY | 13.21 Million USD | -42.91% |
| 2008 Q3 | 14.94 Million USD | -14.6% |
| 2008 Q4 | 13.21 Million USD | -11.59% |
| 2008 Q1 | 20.36 Million USD | -12.0% |
| 2007 FY | 23.14 Million USD | -26.37% |
| 2007 Q4 | 23.14 Million USD | -10.84% |
| 2007 Q3 | 25.95 Million USD | -12.24% |
| 2007 Q1 | 34.33 Million USD | 9.24% |
| 2007 Q2 | 29.57 Million USD | -13.86% |
| 2006 FY | 31.43 Million USD | 27.4% |
| 2006 Q1 | 33.05 Million USD | 33.96% |
| 2006 Q4 | 31.43 Million USD | 9.53% |
| 2006 Q2 | 30.64 Million USD | -7.28% |
| 2006 Q3 | 28.69 Million USD | -6.36% |
| 2005 Q2 | 20.4 Million USD | -9.6% |
| 2005 FY | 24.67 Million USD | -1.99% |
| 2005 Q1 | 22.57 Million USD | -10.32% |
| 2005 Q4 | 24.67 Million USD | 26.74% |
| 2005 Q3 | 19.46 Million USD | -4.62% |
| 2004 Q1 | 17.05 Million USD | 27.22% |
| 2004 Q4 | 25.17 Million USD | -7.82% |
| 2004 Q3 | 27.3 Million USD | 44.23% |
| 2004 Q2 | 18.93 Million USD | 11.02% |
| 2004 FY | 25.17 Million USD | 87.79% |
| 2003 Q4 | 13.4 Million USD | 11.77% |
| 2003 Q3 | 11.99 Million USD | 17.08% |
| 2003 FY | 13.4 Million USD | 121.92% |
| 2003 Q1 | 8.72 Million USD | 44.52% |
| 2003 Q2 | 10.24 Million USD | 17.34% |
| 2002 Q2 | 8.51 Million USD | -20.52% |
| 2002 Q3 | 6.86 Million USD | -19.37% |
| 2002 Q4 | 6.04 Million USD | -11.99% |
| 2002 FY | 6.04 Million USD | -49.81% |
| 2002 Q1 | 10.7 Million USD | -11.02% |
| 2001 Q3 | 8.11 Million USD | -13.03% |
| 2001 Q1 | 10.58 Million USD | -18.99% |
| 2001 Q2 | 9.32 Million USD | -11.89% |
| 2001 Q4 | 12.03 Million USD | 48.36% |
| 2001 FY | 12.03 Million USD | -7.9% |
| 2000 Q4 | 13.06 Million USD | -3.52% |
| 2000 Q2 | 15.27 Million USD | -4.89% |
| 2000 Q3 | 13.54 Million USD | -11.35% |
| 2000 FY | 13.06 Million USD | -7.98% |
| 2000 Q1 | 16.06 Million USD | 13.11% |
| 1999 Q2 | 12.4 Million USD | -10.79% |
| 1999 Q3 | 11.1 Million USD | -10.48% |
| 1999 Q4 | 14.2 Million USD | 27.93% |
| 1999 FY | 14.2 Million USD | -12.88% |
| 1999 Q1 | 13.9 Million USD | -14.72% |
| 1998 Q4 | 16.3 Million USD | -4.12% |
| 1998 Q2 | 9.1 Million USD | -10.78% |
| 1998 Q1 | 10.2 Million USD | -11.3% |
| 1998 Q3 | 17 Million USD | 86.81% |
| 1998 FY | 16.3 Million USD | 41.74% |
| 1997 Q2 | 4.5 Million USD | -21.05% |
| 1997 Q1 | 5.7 Million USD | -18.57% |
| 1997 Q3 | 3.5 Million USD | -22.22% |
| 1997 Q4 | 11.5 Million USD | 228.57% |
| 1997 FY | 11.5 Million USD | 64.29% |
| 1996 FY | 7 Million USD | -44.88% |
| 1996 Q2 | 4 Million USD | -21.57% |
| 1996 Q1 | 5.1 Million USD | -59.84% |
| 1996 Q4 | 7 Million USD | -15.66% |
| 1996 Q3 | 8.3 Million USD | 107.5% |
| 1995 Q4 | 12.7 Million USD | 0.0% |
| 1995 FY | 12.7 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -237.884% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 82.375% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 76.204% |
| Azitra, Inc. | 5.11 Million USD | -278.869% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -94.023% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -20006.649% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -93.442% |
| CEL-SCI Corporation | 30.52 Million USD | 36.515% |
| iBio, Inc. | 28.73 Million USD | 32.55% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 80.815% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -156.13% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 70.446% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -343.338% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -114.534% |
| NanoViricides, Inc. | 12.82 Million USD | -51.144% |
| Oragenics, Inc. | 4.96 Million USD | -290.248% |
| BiomX Inc. | 58.15 Million USD | 66.674% |
| BiomX Inc. | 58.15 Million USD | 66.674% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 77.046% |
| Palatin Technologies, Inc. | 10.74 Million USD | -80.418% |
| Scorpius Holdings, Inc. | 51.03 Million USD | 62.026% |
| Theriva Biologics, Inc. | 60.21 Million USD | 67.812% |